Companies press releases
– Limited to Proposal 3, Amendment to Certificate of Incorporation to Increase Authorized Common Stock – Proposals 1, 2, and 4 were approved at the Annual Meeting – Scheduled to Reconvene July 8, 2021, 9:00 a.m. Eastern Daylight Time Jun 10, 2021, 07:30 ET CRANBURY, N.J., June 10, 2021 /PRNewswire/ — Palatin Technologies, Inc. (“Palatin”) […]
Palatin Announces Adjournment of Annual Meeting of Stockholders Read More »
— Phase 3 Clinical Study of PL9643 in Patients with Dry Eye Disease Planned for Second Half Calendar 2021 — Phase 2 Clinical Study of PL8177 in Patients with Ulcerative Colitis Planned for Second Half Calendar 2021 — Vyleesi Gross Product Sales Up 89%, Net Revenue Up 154%, Prescriptions Increased 24% Compared to Prior Quarter
Primary focus on PL9643 – Phase 3 Clinical Study in Patients with Dry Eye Disease Planned for Second Half Calendar 2021 Webinar on Friday, May 21st at 10:00 am ET May 14, 2021, 07:30 ET CRANBURY, N.J., May 14, 2021 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on
May 13, 2021, 07:30 ET CRANBURY, N.J., May 13, 2021 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter, fiscal year 2021 operating results on Monday, May 17, 2021 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive
May 04, 2021, 07:30 ET CRANBURY, N.J., May 4, 2021 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor systems, today announced that the United States Patent and Trademark Office (USPTO) issued Notices of Final Determination and Requirement for
Palatin Announces U.S. Patent Term Extension for Vyleesi® (bremelanotide injection) Read More »
Positive clinical data from its Phase 2 study of PL9643 in dry eye disease Pre-clinical data with melanocortins for retinal inflammation Apr 20, 2021, 07:30 ET CRANBURY, N.J., April 20, 2021 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin
Mar 05, 2021, 07:30 ET CRANBURY, N.J., March 5, 2021 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor systems, today announced that Carl Spana, Ph.D., President and Chief Executive Officer, will participate in the H.C. Wainwright
— Positive Results from Phase 2 Clinical Study of PL9643 in Patients with Dry Eye Disease — Continue to Rebuild Commercial Infrastructure and Brand Awareness for Vyleesi® — Approximately $72.2 Million in Cash and Cash Equivalents at December 31, 2020 — Teleconference and Webcast to be held on February 17, 2021 at 11:00 AM ET
Feb 12, 2021, 07:30 ET CRANBURY, N.J., Feb. 12, 2021 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter, fiscal year 2021 operating results on Wednesday, February 17, 2021 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its
Application Could Provide U.S. and International Patent Coverage for PL9643, Palatin’s Lead Compound for Dry Eye Disease Phase 2/3 Clinical Trial Currently Planned for Mid-2021 Feb 10, 2021, 07:30 ET CRANBURY, N.J., Feb. 10, 2021 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the
